Abcam's global influence is continuing to grow as the Cambridge firm posted another impressive set of numbers.

Its financial results for the year to the end of June 2017 show reported revenue growth of 26.5%, to £217.1m from £171.7m last year. This is a 9.9% increase on a constant exchange rate basis. Pre-tax profit was £51.9m after the deduction of various costs, up on the £45.4m reported in 2016, meaning shareholders can look forward to a dividend of 10.18p per share, 14% more than 12 months ago.

Abcam CEO Alan Hirzel said: “It has been a year of progress for Abcam as we have once again delivered on our financial goals. We have delivered 10% constant currency revenue growth, meeting our full year guidance, while continuing to invest in the long-term future of the Company. We look forward to continuing to expand our business as we move toward our ambition of becoming the most influential life sciences company for the research communities globally.”

You can keep up to date with all the latest news in and around Cambridge by downloading our free app. It is available for the iPhone and iPad from Apple's App Store , or the Android version can be downloaded from Google Play.